Fox Run Management L.L.C. boosted its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 103.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,100 shares of the biopharmaceutical company’s stock after buying an additional 14,274 shares during the period. Fox Run Management L.L.C.’s holdings in Bellicum Pharmaceuticals were worth $328,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Foresite Capital Management III LLC purchased a new stake in shares of Bellicum Pharmaceuticals during the first quarter valued at approximately $11,328,000. LMR Partners LLP purchased a new stake in shares of Bellicum Pharmaceuticals during the first quarter valued at approximately $3,339,000. Sphera Funds Management LTD. purchased a new stake in shares of Bellicum Pharmaceuticals during the first quarter valued at approximately $2,468,000. Vanguard Group Inc. increased its position in shares of Bellicum Pharmaceuticals by 17.8% in the first quarter. Vanguard Group Inc. now owns 1,061,582 shares of the biopharmaceutical company’s stock valued at $13,100,000 after buying an additional 160,151 shares during the period. Finally, Monashee Investment Management LLC bought a new position in shares of Bellicum Pharmaceuticals during the first quarter valued at about $1,974,000. Institutional investors own 64.96% of the company’s stock.
Bellicum Pharmaceuticals, Inc. (BLCM) opened at 11.76 on Thursday. Bellicum Pharmaceuticals, Inc. has a 12 month low of $9.71 and a 12 month high of $23.11. The firm’s market cap is $389.29 million. The company’s 50-day moving average is $11.66 and its 200 day moving average is $12.67.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.70) by $0.10. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 63.42%. The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.09 million. During the same period in the previous year, the business posted ($0.56) earnings per share. The business’s revenue for the quarter was up 39.1% compared to the same quarter last year. Equities research analysts expect that Bellicum Pharmaceuticals, Inc. will post ($2.84) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Bellicum Pharmaceuticals, Inc. (BLCM) Position Increased by Fox Run Management L.L.C.” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/07/20/bellicum-pharmaceuticals-inc-blcm-position-increased-by-fox-run-management-l-l-c.html.
Several research analysts recently issued reports on the stock. Ladenburg Thalmann Financial Services set a $31.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald set a $32.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. BidaskClub downgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Jefferies Group LLC reduced their price target on shares of Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 9th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Bellicum Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $28.43.
In other news, CFO Alan A. Musso sold 6,311 shares of Bellicum Pharmaceuticals stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $12.24, for a total transaction of $77,246.64. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Ken Moseley sold 13,823 shares of Bellicum Pharmaceuticals stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the sale, the vice president now directly owns 14,314 shares in the company, valued at $175,489.64. The disclosure for this sale can be found here. Insiders have sold 30,134 shares of company stock worth $362,117 over the last three months. Insiders own 23.30% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM).
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.